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a b s t r a c t
Vaccinia virus (VACV) gene F5L was recently identiﬁed as a determinant of plaque morphology that is
truncated in Modiﬁed Vaccinia virus Ankara (MVA). Here we show that F5L also affects plaque
morphology of the virulent VACV strain Western Reserve (WR) in some, but not all cell lines, and not
via previously described mechanisms. Further, despite a reduction in plaque size for VACV WR lacking
F5L there was no evidence of reduced virus replication or spread in vitro or in vivo. In vivo we examined
two mouse models, each with more than one dose and measured signs of disease and virus burden.
These data provide an initial characterization of VACV F5L in a virulent strain of VACV. Further they show
the necessity of testing plaque phenotypes in more than one cell type and provide an example of a VACV
gene required for normal plaque morphology but not replication and spread.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Infection with vaccinia virus (VACV) disrupts numerous cellular
pathways resulting in signiﬁcant changes in cell morphology.
Infection of conﬂuent monolayers of many adherent cell lines
with VACV results in the formation of large circular plaques due to
a combination of cytopathic effects and migration of infected cells.
Three groups of poxvirus genes affect plaque formation. Firstly the
many poxvirus genes that are essential for virus replication are
therefore required for plaque formation. Secondly, plaque forma-
tion is also reliant on spread of infectious extracellular virions (EV)
mediated by actin tails. Therefore, loss of proteins involved either
in morphogenesis or intracellular transport of wrapped virions
(WV), or actin tail formation itself dramatically reduce plaque size
despite production of high levels of mature virions (MV). A third
group of genes is required for normal plaque morphology and size
but less strongly affect virus output in vitro. Analysis of members
of this third group of genes has led to mechanistic insight into
cytoskeletal rearrangements required for cell migration (F11L) and
attachment to the extracellular matrix (C2L and A55R)(Pires de
Miranda et al., 2003; Beard, et al., 2006; Valderrama et al., 2006;
Arakawa et al., 2007a, 2007b; Morales et al., 2008; Cordeiro et al.,
2009; Handa et al., 2013).
VACV mutants with reduced plaque size or altered plaque
morphology typically show altered virulence. Examples include
VACV strain Western Reserve (WR) C16 and B14 (VACWR010/209
and VACWR196 respectively) both of which encode functions
required for normal plaque size and for virulence (Chen et al.,
2006, 2008; Fahy et al., 2008). Likewise, VACVWR with deletions
of BTB/kelch proteins, C2 or A55, forms wild type sized plaques
with indistinct borders and causes altered lesions following
intradermal infection of mice (Pires de Miranda et al., 2003;
Beard et al., 2006). Beyond VACV, plaque size is positively
correlated with case fatality rates for variola virus isolates within
the same clade (Olson et al., 2009). Data such as these have led to a
conventional view that changes to plaque morphology will be
mirrored by in vivo changes to virus replication, spread and/or
virulence.
We have recently identiﬁed F5L as another VACV gene that
inﬂuences plaque morphology and spread during a study based on
strain Modiﬁed Vaccinia virus Ankara (MVA) (Dobson and
Tscharke, 2013). MVA fails to replicate on most mammalian cell
lines (Carroll and Moss, 1997; Drexler et al., 1998), however using a
marker rescue approach, Wyatt et al. (1998) generated a set of
recombinant MVAs (rescued MVAs) with improved replication on
a range of mammalian cells. We identiﬁed F5L, which is truncated
in MVA but repaired in some of the rescued viruses, as a gene
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responsible for signiﬁcant differences in plaque morphology across
this set of rescued MVA strains (Dobson and Tscharke, 2013).
Further experiments found that while repair of F5 was associated
with signiﬁcant changes in plaque morphology it had no discern-
ible effect on replication in vitro (Dobson and Tscharke, 2013). F5L
remains poorly characterized, but an early description of the VACV
HindIII F region and the most accurate VACV-genome wide
transcriptomic study found that it is expressed early after infection
(Roseman and Slabaugh, 1990; Yang et al., 2010). F5 is not a
component of mature virions (MV) (Chung et al., 2006; Yoder
et al., 2006; Resch et al., 2007; Manes et al., 2008) and a large
yeast-two-hybrid study found no interactions between F5 and
other VACV proteins (McCraith et al., 2000).
It was possible that the role found for F5 in the context of MVA
was inﬂuenced by one or more of the many other genetic changes
in MVA compared to most virulent VACV strains. Further, studies
of virulence based on viruses with the MVA genetic background
will be complicated by the loss of many virulence functions, some
known and others yet to be deﬁned (Blanchard et al., 1998). Indeed
a recent report demonstrated that the rescued MVAs were highly
attenuated and the rescued strain with the largest plaque was
no more virulent than MVA in an intranasal infection model,
even in immunocompromised mice (Melamed et al., 2013).
To address these issues, we explored the function of F5L in
VACVWR. In this virulent VACV strain, F5 is required for normal
plaque size and morphology in multiple cell lines, but was not
required for replication or spread in any cells in vitro, nor for
virulence in vivo.
Results
Conservation of F5 across the poxviruses and similarity
to known proteins
F5L (also annotated as VACWR044) encodes a 322 aa protein in
VACVWR. F5 contains a predicted signal sequence, with a cleavage
site between aa 20 and 21 (Signal P 3.0 (Bendtsen et al., 2004)) and
a putative transmembrane domain at the carboxyl-terminus (aa
287-311) (TMHMM (Krogh et al., 2001)). Orthologs are found in all
members of the orthopoxvirus genus for which genome sequence
is available except ectromelia virus (Viral Orthologous Clusters,
(Upton et al., 2003)). The taterapoxvirus homolog is truncated to
193 aa and therefore lacks the putative transmembrane domain
(GenBank Accession number NC_008291). No signiﬁcant homologs
are found outside the genus (BLASTp, E value o0.001). Beyond the
poxviruses, the amino terminus of F5 contains a region with
similarity to immunoglobulin V-set domain containing proteins,
but this does not reach the signiﬁcance threshold (E value¼
0.00036) (Pfam (Finn et al., 2010)). Variation exists amongst F5L
homologs from various strains of VACV (Fig. S1). For example, F5L
from the VACV strain referred to as Ankara, used to rescue MVA for
growth on BS-C-1 cells (Wyatt et al., 1998) and for our description
of a role for F5 in the context of MVA (Dobson and Tscharke, 2013),
encodes a 321 amino acid protein due to a 3 bp deletion. In
addition to this difference, 10 nucleotide substitutions are present
in Ankara F5L compared with VACVWR, resulting in four amino
acid changes.
Deletion of F5L affects plaque morphology but not replication
of VACVWR
A VACVWR strain with 86% of the F5L ORF deleted
(VACVWRΔF5L) and a revertant (VACVWRF5Lrev) were made,
demonstrating that F5 is non-essential for VACVWR growth in
culture. However, plaques formed by VACVWRΔF5L were
approximately 30% smaller than the parent or VACVWRF5Lrev
on BS-C-1 cells. Cell clearance from the center of plaques was
reduced and the distinctive halo of contracted cells that usually
surround VACV plaques (Cordeiro et al., 2009) was absent (Fig. 1a
and d). Further, live microscopy showed that the expansion rate of
plaques was slower in the absence of F5 (Fig. 1c). VACVWRΔF5L
also formed smaller plaques on RK13, IEC-6, and 293A cells
(Fig. 1b,e,f and 6b). By contrast, we observed no difference in
plaques formed on primary human foreskin ﬁbroblasts, BHK-21 or
the murine cell line NIH/3T3 (Fig. 1b, and data not shown).
To determine whether loss of F5 affected virus replication, a
high multiplicity (m.o.i.¼5) growth experiment was done (Fig. 2a).
This found no decrease in replication associated with the loss of
F5. We then used multiple-step experiments (m.o.i.¼0.01) to
measure replication and spread. These found that deletion of F5L
had no effect on either cell associated, or supernatant virus yield in
BS-C-1 (Fig. 2b) or primary human foreskin ﬁbroblasts (HFF) (data
not shown). To probe replication and spread more stringently,
inocula were reduced to approximately 50 p.f.u. in a 9.5 cm2
culture of BS-C-1, so that spread would not be inhibited by a lack
of infectable cells. Even in this experiment with six replicates, no
statistically signiﬁcant difference in virus output per plaque was
across the parent, VACVWRΔF5L and VACVWRF5Lrev or between
any pair of viruses at 72 h post infection (h.p.i.)(Fig. 2c). This last
experiment was repeated and again no signiﬁcant differences
were found. Taken together, these experiments suggest that F5
has no discernible role in VACVWR replication or spread in in vitro
culture, even on a cell line where it is required for normal plaque
morphology.
Localization of the F5 protein in infected cells
In order to test the predicted cell membrane localization of F5
we produced VACVWR/F5LGFP in which the native F5 was
replaced with an F5-eGFP fusion. This virus had a plaque pheno-
type similar to VACVWR on BS-C-1 cells (Fig. S2), demonstrating
that F5 function is intact in this virus. There was diffuse ﬂuores-
cence in cells infected with VACVWR/F5LGFP at several times after
infection up to 8 h.p.i., but across multiple images we were unable
to determine the localization with any certainty. The only common
pattern that was evident across all images emerged from 6 to 8 h.
p.i. and was an enrichment of eGFP at the periphery of the cell
where thin cytoplasmic extensions are evident. This localization
was restricted to regions in contact with neighboring cells,
suggesting cell–cell contact might stabilize or recruit F5 (Fig. 3).
This pattern of staining was not seen in cells infected by VACVWR
expressing eGFP not fused to F5L, but was conﬁrmed for F5-eGFP
by total internal reﬂection ﬂuorescence (TIRF) microscopy (not
shown). To further deﬁne the location of F5-eGFP ﬂuorescence,
cells were stained for actin (phalloidin and cortactin), the cell-to-
cell junction marker β-catenin, or phosphotyrosine as a marker of
focal adhesions. In each case projections marked with eGFP were
noted, but these failed to co-localize with any of the host cell
markers (Fig. 3). Finally, F5-eGFP did not colocalize with B5, a
marker for enveloped virus (EV) or the virus factory, as shown by
the DNA stain DAPI, where intracellular mature virus is assembled
(Fig. 3 row 3 and other rows respectively).
F5L is not required for actin tail formation, Ca2þ independent cell
adhesion or cell migration
Deletion of viral genes has identiﬁed three mechanisms asso-
ciated with alterations in VACV plaque size and appearance which
are not always matched by a measureable reduction in virus yield:
(1) ability to make actin tails, (2) loss of adhesion of infected cells
in the absence of Ca2þ and (3) altered cell migration of infected
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cells. We considered whether deletion of F5 might act by these
mechanisms, addressing each in turn below.
1. VACV morphogenesis is complicated and several forms of
infectious virus are made. The form of virus implicated in virus
spread in vivo is wrapped with an additional membrane (EV)
and is able to be released from infected cells, or propelled into a
neighboring cell by an actin tail (Roberts and Smith, 2008;
Welch and Way, 2013). Loss of certain proteins incorporated
into the outer membrane of EV dramatically reduces plaque
size as a result of decreased EV production, reduced infectivity of
the virus released, or decreased production of actin tails (Blasco
and Moss, 1991; Duncan and Smith, 1992; Engelstad and Smith,
1993; Wolffe et al., 1993, 1997; McIntosh and Smith, 1996; Roper et
al., 1998; Ward and Moss, 2001). Likewise, viruses lacking other
genes required for efﬁcient assembly and transport of WV or for
actin tail formation, have very small plaques (Rodriguez and Smith,
1990; Parkinson and Smith, 1994; Wolffe et al., 1998; Zhang et al.,
2000; van Eijl et al., 2002; Domi et al., 2008; Dodding et al., 2009;
Morgan et al., 2010). We noted that the effect of F5L on plaque size
BS-C-1
5
10
15BS-C-1
W
R
BS-C-1 BS-C-1
BS-C-1
4
5
WR ΔF5L F5Lrev
0
(μ
m
 / 
hr
)
E
xp
an
si
on
 S
pe
ed
Pl
aq
ue
 E
W
R
Δ
F5
L
WR ΔF5L F5Lrev
0
1
2
3
(m
m
2 )
Pl
aq
ue
 a
re
a 
(
W
R
F5
Lr
ev
IEC-6 NIH3T3RK13
RK13
W
R
1
2
3
4
5
WR ΔF5L F5Lrev
0P
la
qu
e 
ar
ea
 (m
m
2 )
P
IEC-6
4
6
8
W
R
F5
Lr
ev
W
R
Δ
F5
L
WR ΔF5L F5Lrev
0
2
ar
ea
 (m
m
2 )
Pl
aq
ue
 a
Fig. 1. Deletion of F5L affects plaque phenotype on several cell lines. Plaque formation on BS-C-1, RK13, IEC-6 or NIH/3T3 cells by VACVWR, VACVWRΔF5L and
VACVWRF5Lrev. (a and b) Representative plaques formed under semisolid media were immunostained, crystal violet stained or photographed unstained. Scale bar 300 mm.
(Original magniﬁcation: 40 ). (c) Average plaque expansion speed on BS-C-1 is indicated by the solid line. The expansion of the leading edge of plaques was monitored from
16 to 56 h.p.i. using live-cell microscopy. One-way ANOVA (n¼53, Po0.0001) and Tukey pairwise test (nnnpo0.001). (d–f) Average area of immunostained plaques formed
under semisolid media on BS-C-1, RK13 or IEC-6 is indicated by the solid line. One-way ANOVA (n¼20) and Tukey pairwise test (nn po0.01, nnnpo0.001). (e).
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was not as strong as published reports for these genes. Further-
more, F5 appeared not to be required for EV production and
release because similar amounts of virus were found in the
supernatant of cells infected with VACVWRΔF5L, its parent and
the revertant (Fig. 2b). When ‘comet’ plaque assays were done
with liquid overlay so that secondary plaques can be formed by
released EV, the morphology of the primary and small secondary
plaques but not the extent of secondary plaque formation was
dependent on F5 (data not shown). Finally, actin tails were
observed directly for our viruses. As shown in Fig. 4a, no signiﬁcant
difference in actin tail length was found between VACVWRΔF5L
and VACVWRF5Lrev (Fig. 4a).
2. When Ca2þ is depleted from the growth medium, uninfected
BS-C-1 cells lose the ability to adhere to the extracellular
matrix and round up, but this process is inhibited by VACV
infection (Sanderson and Smith, 1998). The A55 and C2 proteins
of VACVWR are required for VACV-induced Ca2þ-independent
cell adhesion. Like F5L, deletion of C2L or A55R alters plaque
morphology without substantially affecting in vitro replication
and plaques formed by VACVWRΔF5L appeared similar to
published images of the VACVWR mutants, vΔC2 and vΔA55,
so we wondered if F5 was required for Ca2þ-independent
adhesion (Pires de Miranda et al., 2003; Beard et al., 2006).
BS-C-1 cells were infected with VACVWR, VACVWRΔF5L, or
VACVWRF5Lrev for 18 h before Ca2þ was sequestered by
adding EDTA to the medium and then adhesion of cells was
monitored over 20 min (Fig. 4b). Uninfected cells rapidly lost
adhesion and rounded up. By contrast, the majority of virus-
infected cells remained strongly adherent and the absence of F5
had no effect on this Ca2þ-independent adhesion.
3. VACV infection induces migration of cells and protein F11 is
involved in the cytoskeletal rearrangements required for this
motility (Valderrama et al., 2006; Morales et al., 2008; Cordeiro
et al., 2009; Handa et al., 2013). As a result, deletion of F11L
from VACVWR reduces plaque size (Morales et al., 2008;
Cordeiro et al., 2009; Handa et al., 2013) and cells infected
with MVA, in which F11L is fragmented, do not migrate into a
wound made in a monolayer of serum starved BS-C-1 cells
(Valderrama et al., 2006; Zwilling et al., 2010). Initial live
microscopy suggested that F5 was not required for cell motility
(not shown) but to test this more quantitatively we mea-
sured migration of BS-C-1 cells infected with VACVWRΔF5L,
VACWRF5Lrev, or VACVWR using a scratch wound assay
(Fig. 5a and b). Compared to mock-infection, all viruses induced
signiﬁcant migration of cells into the wound, irrespective of
deletion of F5L. To ensure that this assay was sensitive to
impairment of migration, we extended the assay to include
several viruses based on MVA made in the process of mapping
F5 as a determinant of plaque morphology in this strain. These
viruses were v51.2/F11LGb, in which F11L was repaired; v51.2/
F5LGb and v51.2/F5L, in which F5L was repaired; v51.2/F5L-
F11L, in which F5L and F11L were repaired ((viruses with ‘Gb’ in
their name retain a GFP/bsd selectable marker downstream of
the repaired gene) (Dobson and Tscharke, 2013). In agreement
with the literature, only cells infected with viruses that had an
intact F11L gene migrated into the wound. Presence or absence
of F5 had no impact on migration either alone or in combina-
tion with F11 across this set of viruses (Fig. 5c).
Virus infection is needed for F5 stability, but the predicted cytoplasmic
tail is not required for function in vitro
In order to study the effect of F5 expression on uninfected cells,
we produced two F5-eGFP fusions expressed from the CMV IE
promoter. The fusions contained either a full length (322 aa) or
truncated (218 aa) F5L from VACVWR and were tagged on their c-
termini with eGFP (pEGFP-N1::F5L and pEGFP-N1::F5L218, respec-
tively). F5L218 contains at Ser218Pro mutation such that the
protein produced is identical to the predicted MVA F5 homolog
(MVA034), and lacks 104 aa of the c-terminus, including the
putative transmembrane domain. No differences in cell morphol-
ogy were observed between 293A cells transfected with pEGFP-
N1::F5L, pEGFP-N1::F5L218 or the empty control vector (not
shown). The brightness of ﬂuorescence in cells transfected with
these constructs was in the order, empty pEGFP-N14pEGFP-N1::
F5L218» pEGFP-N1::F5L. To test if F5-eGFP instability in uninfected
cells was contributing to the weak ﬂuorescence, cells were mock-
infected or infected with VACVWRΔF5L, 3 h after transfection
(Fig. 6a). Infection greatly increased ﬂuorescence in cells expres-
sing full length F5-eGFP, despite this construct being under control
of the CMV IE promoter. By contrast and as expected for genes
transcribed from the nucleus, eGFP ﬂuorescence from theF5L218-
GFP and the empty vector control construct was reduced by VACV
infection. Thus the order of brightness after VACV infection was
pEGFP-N1::F5L » empty pEGFP-N1 and pEGFP-N1::F5L218. In
further experiments, F5L-eGFP brightness, but not that of the
other two constructs was improved by VACVWR infection in the
presence of AraC (data not shown). Together these experiments
Fig. 2. Deletion of F5L does not affect replication in vitro. (a) Single step growth
analysis (m.o.i.¼5) in BS-C-1, cell associated virus is shown. (b) Multiple step
growth analysis (m.o.i.¼0.01) in BS-C-1, cell associated virus shown in black, virus
in the supernatant is in gray. Data points are representative of three independent
wells. Mean7SEM. (c) Average virus yield per plaque 72 hpi after infection of BS-C-
1 with approximately 50 pfu/well is indicated by the solid line. Cell associated virus
shown in black, virus in the supernatant is in gray.
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suggest that full length F5 requires another function expressed
early in VACV infection for stability in cells, but this depends on
sequences in F5L from WR that are not present in the truncated
version expressed by MVA.
Next, a complementation assay was used in which F5L fused to
GFP was expressed from a plasmid under its natural promoter in
cells infected by VACVWR or VACVWRΔF5L to determine if any
domains were dispensable for function. Similar complementation
assays have been used by others, including for genes with VACV
early promoters, even though the early transcription factors are
thought to be mostly sequestered in the virus cores (Cochran et al.,
1985; Valderrama et al., 2006). The plasmid also encoded mCherry
under the VACV strong synthetic promoter (pSS), which was
brighter than F5-eGFP to more easily identify cells that received
virus and the plasmid at low magniﬁcation. A plasmid containing
F5-eGFP, but not the empty vector was able to rescue the plaque
defect of VACVWRΔF5L on 293A cells demonstrating expression of
functional F5 (Fig. 6b). Next, we tested the ability of a set of
plasmids expressing F5-eGFP with regions of F5 deleted to rescue
the plaque defect of VACVWRΔF5L. The predicted features of F5
covered by these deletions were the signal sequence, the extra-
cellular domains (broken into four segments) and the short
cytoplasmic tail (Fig. 6c). Of these constructs, only the cytoplasmic
tail deletion was still able to rescue the plaque size of
VACVWRΔF5L, but eGFP ﬂuorescence was always seen (Fig. S3).
These experiments suggest that the putative cytoplasmic tail is not
required for the function of F5 in plaque morphology.
F5L does not affect VACV pathogenesis, replication or spread in mice
We examined the role of F5 in VACV virulence using two
murine models of infection. First, BALB/c mice were infected
intradermally with VACVWR, VACVWRΔF5L or VACVWRF5Lrev
and lesion size monitored over 21 days (Fig. 7a). All viruses
produced lesions at the infection site, but there was no difference
in size between VACVWRΔF5L and controls. Virus replication over
the ﬁrst 5 days was also tested in this model, with doses of 1104
p.f.u. and 1102 p.f.u.. A titer of around 1107 p.f.u. was achieved
irrespective of inoculum or virus, showing that F5 does not
increase VACV replication in vivo in mice (Fig. 7b).
Second, the intranasal model of infection was used. Three
experiments were done with a dose of 1104 p.f.u. and there
were no statistically signiﬁcant differences in weight loss or
number of mice that were euthanized due to loss of 430% of
starting weight between VACVWRΔF5L and the control viruses
(Fig. 8a). A lower dose of 1103 p.f.u. was then used to tease out
any small difference between viruses, but again no consistent
phenotype was found for VACVWRΔF5L (Fig. 8a). Virus titers were
measured at 3, 7 and 10 days after intranasal infection with 1104
p.f.u. of VACVWR, or VACVWRF5Lrev, examining lungs, brain,
spleen (Fig. 8b), ovaries and liver (not shown). No signiﬁcant
difference in titer was found between the groups of mice for any
organ at any time. Finally we tested several parameters of
immunity in mice infected intranasally with VACVWRΔF5L and
controls. There were no differences in: (a) the total VACV-speciﬁc
IgG response as measured by ELISA (Tscharke et al., 2002); (b) the
memory CD8þ T cell response in the spleen as measured by
production of IFN-γ after stimulation with VACV peptide epitopes
(Flesch et al., 2012a, 2012b); (c) inﬁltrates present in brochoalveo-
lar lavage taken at various times after infection (Reading and
Smith, 2003) (data not shown).
Discussion
We demonstrate here that VACV gene F5L is a determinant of
plaque morphology in VACVWRwhen grown on a subset of cell lines
tested, but does not contribute to virus replication in vitro in these
same cells or to pathogenesis in mice. Taken at face value, smaller
plaques in the absence of F5 suggest that this protein is required for
normal spread of virus. However, no detectable change to replication
in vitrowas found despite using very low input titers to maximize the
Fig. 3. Localization of F5. HeLa cells were infected with VACVWR/F5LGFP (m.o.i.¼5) ﬁxed at 8 h.p.i., stained with Alexa Fluor 568-phalloidin (Aph, actin), anti-β-catenin (cell-
to-cell junctions), anti-phosphotyrosine (focal adhesions) or anti-cortactin (actin-cytoskeleton rearrangements) along with DAPI or anti-VACV-B5 (B5) (row 3) and imaged
(100 objective) to analyze the localization of F5L-GFP.
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inﬂuence of virus spread. In addition, there was no defect in the
ability of VACVWRΔF5L to replicate at primary sites of infection in
mice, as seen in skin and lungs after intradermal and intranasal
infection respectively, nor was there a defect in virus dissemination.
In the case of the intradermal infection the above held true where
the inoculated dose was as low as 100 p.f.u. and virus growth
exceeded ﬁve orders of magnitude in 5 days, a very robust test of
replication in vivo. It remains possible that deletion of F5L is
associated with a very subtle reduction in virus production or spread
that was beyond our sensitivity to dissect, but it is unclear that such a
small difference would be important for the outcome of infection.
Another important point highlighted by this study is that the effects
of virus genes on plaques can be cell type-speciﬁc. We observed no
difference in plaque size or morphology between VACVWRΔF5L and
the wild type VACVWR when grown on BHK-21 (hamster), NIH/3T3
(mouse), or HFF (human), in contrast to the clear and reproducible
differences seen for BS-C-1 (African green monkey), RK13 (rabbit),
IEC-6 (rat) and 293A (human) (Figs. 1 and 6b). A further set of cell
lines including HeLa (human), Vero (African green monkey), L-cells
(mouse) and L-Db (derivative of L-cells) made small and relatively
variable plaques, or only foci, with all viruses making assessment of
morphological differences associated with F5 inconclusive. There is
no obvious species speciﬁcity across this wide range of cells, but
some correlation with cell shape was noticed: F5 affected the round,
regular plaques formed on cells that have cobble-stone or cuboid
shapes when conﬂuent and uninfected. By contrast, F5 had no affect
on cells with more elongated (primary ﬁbroblastoid-like) forms
when conﬂuent and on which VACV makes somewhat irregular
plaques. This observation may have some relevance for the
function of F5.
A range of VACV genes has been characterized as being required
for normal plaque morphology but when deleted have a minor
(less than 10-fold) or undetectable effect on virus yield in multiple
step growth curves. These include A55R, C2L (indistinct borders on
BS-C-1) (Pires de Miranda et al., 2003; Beard, Froggatt, and Smith,
2006); C11R (10–30% smaller plaques on BS-C-1) (Buller et al.,
1988), VACVWR010/209 (approximately 20–30% smaller plaques on
BS-C-1 and RK13) (Fahy et al., 2008), O1L (plaques approximately
50% smaller on 293A) (Schweneker et al., 2012) and VACWR196
(smaller plaques on BSC-1 (20%) and CV-1(40%)) (Chen et al., 2006).
However, in each case viruses lacking these genes had altered
pathogenesis in at least one model of infection in mice. In contrast
for F5, over a total of six experiments across two models, no
consistent role in virulence was observed, nor could an inﬂuence of
this protein be found on three parameters of the immune response.
The only other VACV protein associated with a plaque phenotype
and not virulence is another membrane associated protein, A38,
but pathogenesis was only assessed in a single model (Parkinson et
al., 1995). There is a range of other VACV genes for which deletion
does not change pathogenesis in mice, for example A45R, B9R and
B12R, but in these cases there is a similar lack of phenotype for the
deletion virus in vitro (Banham and Smith, 1993; Almazan et al.,
2001; Price et al., 2002; Tscharke et al., 2002). An example of a
VACV proteinwith a known function that fails to alter pathogenesis
in well controlled studies in mice is B8. B8 binds IFNγ from many
species, but not mice, explaining its lack of function in mouse
models (Alcamí and Smith, 1995; Symons et al., 2002). However,
the B8R ortholog in the mouse-speciﬁc pathogen ectromelia virus
does bind mouse IFNγ and deletion from this virus reduces
virulence (Sakala et al., 2007). We speculate that F5 may lack a
binding partner in this species, in support of this we saw no plaque
defect in the absence of F5 on mouse NIH/3T3 cells, although we
did observe a difference on another rodent cell line, IEC-6. It is
interesting to note that ectromelia virus, a mouse-speciﬁc ortho-
poxvirus lacks an F5L homolog. However, at the same time a role
for virulence in mice has been shown for VACV genes K7R and A40R
that are fragmented and therefore also non-functional in ectrome-
lia virus (Tscharke et al., 2002; Benﬁeld et al., 2013). It remains
unlikely that VACV would maintain a gene that has no role in an
in vivo setting, therefore it may be of value to investigate F5
function in another host species. Assuming such a function is
found, it would be of interest to determine if it can be related in
any way to the role for F5 revealed in plaque morphology here.
While we have not deﬁned how F5 contributes to plaque
formation, its role is non-redundant and its mode of action is
distinct from previously deﬁned mechanisms. Firstly, there was no
evidence that F5 plays any role in virion morphogenesis, EV
release or actin tail formation. Secondly, unlike F11, F5 did not
affect cell motility as captured by a scratch wound assays. Finally,
unlike C2L or A55R, deletion of F5L from VACVWR does not reduce
Ca2þ-independent binding of cells to extracellular matrix. From
the predicted structure, apparent localization to cell–cell contacts
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and lack of requirement for the putative intracellular portion we
speculate that F5 functions via interactions with proteins on
neighboring cells or extracellular matrix elements. However, this
remains to be determined.
In summary, we identify F5 as a determinant of plaque
phenotype in a virulent strain of VACV and the data presented
provide a foundation for further work on this previously unchar-
acterized protein. Finally, our investigations of F5L are a reminder
that small plaque phenotypes should be checked in multiple cell
lines and cannot always be assumed to be a correlate of virus
replication and spread.
Methods
Cells and virus
All cells were maintained in Dulbecco's modiﬁed Eagle medium
(DMEM; Gibco/Invitrogen) with L-glutamine and 10% FBS (D10),
except for BHK-21 (Minimum Essential Medium (Gibco/Invitrogen)
with L-glutamine and 10% FBS). Lipofectamine 2000 (Invitrogen)
was used for all transfections. VACV stocks were grown in BHK-21
in DMEM with L-glutamine and 2% FBS (D2) and puriﬁed by
centrifugation through a 36% sucrose cushion. Virus titers were
determined by plaque assay on BS-C-1.
Plasmid construction
PCR was used to generate inserts for InFusion (Clontech)
or conventional cloning. In descriptions below, PCR primers for
(a) InFusion contain 15 bp matching ﬂanking vector sequence
(underlined) or a neighboring insert (bold); (b) conventional
ligations include restriction enzyme sites (italics).
Generation of recombinant VACV
General strategy: All recombinant VACV were produced by infec-
tion of 293A cells with the appropriate parent virus (m.o.i.¼0.05)
followed by transfection 1 h later with 1 mg of plasmid DNA. After 2 h
at 37 1C transfection media was replaced with 2 ml D2. Cells were
harvested 2 days later. Plaque puriﬁcation was carried out on BS-C-1
in phenol-red free D2-CMC. PCR screening and sequencing was used
to conﬁrm the correct modiﬁcation had occurred and identify plaque
picks free of parental virus. Two independent recombinant viruses
were isolated from parallel infection/transfection experiments.
VACVWRΔF5L and VACVWRF5Lrev: VACVWRΔF5L was engi-
neered using transient dominant selection for the GFP-bsd marker
gene from plasmid pSSGb (Wong et al., 2011). Sequences ﬂanking F5L
were ampliﬁed from VACVWR DNA with: Left ﬂank: F5LLfwd:
CAGTGTGCTGGAATTCTCACTATTCCGTCACTGGCTG and TTAAACCGCAT-
CAAGCAGCACCCATGAATGTCGAT; Right: CTTGATGCGGTTTAATAAATG
TT and F5LRrev: GATATCTGCAGAATTCTGCTGTGGTAGATTCTGTGACG.
The last 134bp of F5L were preserved to maintain the promoter of
F4L. VACVWRF5Lrev was produced by recombination between a
linearized pSSGb vector containing the full F5L reading frame plus
homology arms (PCR product of F5LLfwd and F5LRrev) and the
VACVWRΔF5L genome.
VACVWR/F5LGFP: To produce an eGFP-tagged version of the F5
protein, a plasmid construct (pSSmCB::F5LGFPnoM) was created
with F5L fused to the 50 end of EGFP (without initiation codon),
plus the left and right ﬂanking sequences used in the produc-
tion of VACVWRΔF5L. The left ﬂank (homL) was ampliﬁed from
VACVWR DNA using TCTAGAGTCGCGGCCTCACTATTCCGTCAC
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TGGCTG and ACAAGTAAAGCGGCCTTGTAGTGATTGCGGCGAT and
cloned into pEGFP-N1 linearized with NotI; producing pEGFP-
N1::homL. The eGFP gene from the second codon plus homL was
then ampliﬁed using pGFP: GTGAGCAAGGGCGAGGAG and
F5LLfwd. The F5L ORF along with the right homology arm was
ampliﬁed from VACVWR DNA using CTCGCCCTTGCTCACGTTATC-
TATATGCCTGTACTTGGAT and F5LRrev. The eGFP-homL and F5L
PCR products were cloned into the unique EcoRI site in the MCS of
pSSmCB (pSSGb from Wong et al., 2011 with eGFP replaced by
mCherry). After recombination with VACVWRΔF5L, GFPþ plaques
with wild type plaque morphology were selected.
Evaluation of VACV plaques
Plaque size: conﬂuent cell monolayers in six-well plates were
infected with 50 p.f.u. virus. After 2 h at 37 1C, the inoculum was
replaced with semisolid D2þ0.4% (w/v) carboxy-methyl cellulose
(D2-CMC). Cells were ﬁxed and immunostained with anti-MVA
antibody followed by an anti-rabbit secondary antibody conju-
gated to horseradish peroxidase (Staib et al., 2004). Plaque-
expansion speed: Conﬂuent BS-C-1 monolayers were infected
with 50 p.f.u in glass-bottom six-well plates (MatTek). After 1 h,
cells were washed with PBS and Leibovitz's L-15 (Invitrogen) with
L-glutamine and 10% FBS was added. Plaques were identiﬁed in the
monolayers from 14 h.p.i. and the leading-edge of each plaque was
imaged every hour from 16 to 56 h.p.i. using an Olympus CellR
Live-Cell Microscope (5 objective). Plaque areas and expansion
speeds (mm h1) were calculated for each virus strain using Image
J (v1.46j) (Rasband, 1997-2012).
Replication in vitro
Conﬂuent monolayers in six-well plates were infected with
either 1104 p.f.u. (multiple step growth curve; m.o.i.¼0.01) or
5106 p.f.u (single step growth curve; m.o.i.¼5) virus in 1 ml D2.
After 1 h at 37 1C, unabsorbed virus was removed, cell monolayer
washed once, and 2 ml fresh media added. 0 h samples were
harvested immediately after addition of fresh media. Further wells
were harvested at the indicated time points. Cells were harvested
into existing media, centrifuged at 931 g for 10 min to separate
cell-associated and supernatant virus, which were titrated sepa-
rately. To calculate mean virus output per plaque, 9.5 cm2 wells of
conﬂuent BS-C-1 were infected with 500 ml of virus diluted to
1102 p.f.u./ml in D2. After 90 min, the inoculum was replaced
with 2 ml D2 without CMC (6 wells per virus), or D2-CMC (3 wells
per virus). 72 h.p.i. wells without CMC were harvested and virus
titrated. Wells with D2-CMC were stained with crystal violet and
plaques counted.
Antibodies and ﬂuorescent chemicals
Primary antibodies used for immunoﬂuorescence assays were
anti-B5 (Schmelz et al., 1994), anti-phosphotyrosine (4G10; Che-
micon), anti-cortactin (4F11, Upstate Biotechnology), anti-ß-
catenin (610154, BD Transduction Laboratories). The secondary
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antibodies (Invitrogen) were Alexa Fluor 568-conjugated goat
anti-mouse IgG, Alexa Fluor 568-conjugated goat anti-rabbit IgG,
and Alexa Fluor 350-conjugated goat anti-rat IgG. Fluorescent
chemicals used were DAPI (Sigma-Aldrich) (1 mg ml1) and Alexa
Fluor 568-phalloidin (Invitrogen) (1:300 dilution). All antibodies
were diluted in blocking buffer (1% BSA and 2% FBS in cytoskeletal
buffer (CB) [10 mM MES buffer, 0.15 M NaCl, 5 mM EGTA, 5 mM
MgCl2, 50 mM glucose, pH 6.1]).
Immunoﬂuorescence microscopy
Cells were seeded on glass coverslips, infected with appropriate
viruses and ﬁxed at 8 h.p.i. with 3% paraformaldehyde (PFA) in CB
for 10 min at room temperature. Before staining, cells were
permeabilized with 0.1% Triton X-100 in CB (or not permeabilized
as indicated). Cells were incubated in blocking buffer for 20 min,
suitable primary antibodies for 40 min, washed three times in PBS,
then incubated in secondary antibodies for 20 min. The coverslips
were mounted on a glass slide with 1% (w/v) p-phenylenediamine
(Sigma-Aldrich) in Mowiol mounting medium (10% (w/v) poly-
vinyl alcohol 4-88 [Sigma-Aldrich], 25% (w/v) glycerol, 0.1 M Tris,
pH 8.5). Fluorescence was performed with an Olympus microscope
BX51 with ﬁlter sets 31001, 31002, and 31013v2 (Chroma). Actin-
tail lengths were measured with Image J (v1.46j).
Wound healing assays
Conﬂuent BS-C-1 cells on glass coverslips were serum starved in
DMEM without FBS (D0) for 2 h, then infected (m.o.i.¼5). 1 h.p.i.,
wounds were created with a yellow tip and cells were washed in PBS
and rescued in D0. Cells were ﬁxed at 24 h.p.i. with 3% PFA in CB for
10 min, stained with DAPI and Alexa Fluor 568-phalloidin and
mounted (as described above). All wounds were imaged with an
Olympus microscope BX51 (10 objective), and an average wound
size was calculated for mock infected cells. The number of cells
containing DAPI stained nuclei within each wound was counted.
Calcium independent cell adhesion
Extracellular calcium was depleted by addition of EDTA
(Sanderson and Smith, 1998). Conﬂuent BS-C-1 monolayers were
infected with the appropriate virus (m.o.i.¼3). 18 h.p.i. cells were
washed three times with PBS, then 1 ml of PBS containing 10 mM
EDTA was added to each well. Cells were incubated at 37 1C for 3,
10 or 20 min. Photographs of three randomly selected ﬁelds were
taken on a phase contrast microscope (100magniﬁcation).
Rounded up and adherent cells in the top left quadrant of each
image were counted (155–450 cells).
Transient rescue of VACVWRΔF5L plaque morphology
pSSmCB::F5LGFP encodes the full length F5L-GFP fusion under the
F5L promoter. F5L-GFP fusion and promoter were ampliﬁed from
pSSmCB::F5LGFPnoMwith EGFPstop: CAGTGTGCTGGAATTCTTACTTG-
TACAGCTCGTCCATG and F5LRrev, and cloned into pSSmCB linearized
with EcoRI. From pSSmCB::F5LGFP ﬁve further plasmids were con-
structed by ampliﬁcation of the whole plasmid using phosphorylated
primers. Plasmids contained deletions of amino acids (aa) 2–17, 25–
69, 75–144, 145–225, or 226–261. A plasmid containing F5L-GFP with
a deletion of aa 315–322 was produced by splice overlap PCR using:
CTCGCCCTTGCTCACTCTTTTGTACATCGATATCGC and F5LRrev, and
EGFPstop and pGFP (external primers in bold), followed by cloning
into pSSmCB linearized with EcoRI. 293A cells were infected with 50–
100 p.f.u. of VACVWR or VACVWRΔF5L, then transfected 1 h later
with 2 mg of plasmid DNA. Transfection media replaced after 3.5 h
with phenol-red free D2-CMC. 48 h.p.i. ﬂuorescent plaques were
photographed.
Expression of F5 in uninfected cells
Full length (F5L) or truncated (F5L218) F5L, ampliﬁed from
VACVWR DNA with: CGCGGGCCCGGGATCAACATTTATTAAACCG-
CATCAAG and either F5full: GGCGACCGGTGGATCGTTATCTATATG-
CCTGTACTTGGAT or F5218: GGCGACCGGTGGATCTGGAAACAGA-
TAACAAGAAAACTCGTC, were cloned into pEGFP-N1. 293A cells
were transfected with 2 mg of pEGFP-N1, pEGFP-N1::F5L, or
pEGFP-N1::F5L218. Three hour post transfection, media was
replaced with D2 for uninfected wells or VACVWRΔF5L or MVA
(m.o.i¼5). 1 h.p.i. inoculum was replaced with 2 ml/well phenol-
red free D2. After overnight incubation at 37 1C, cells in the media
were collected, while attached cells were washed with PBS and
then removed using trypsin. Pooled cells were washed once with
PBS, ﬁxed using 1% PFA, and washed. eGFP ﬂuorescence was
measured using an LSR II ﬂow cytometer (BD Biosciences) and
data analyzed using FlowJo software (Tree Star Inc.). For inhibition
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of intermediate and late gene expression, overnight media con-
tained 40 mg ml1 AraC.
Mice and infections
Mice were housed and all experiments carried out in compliance
with ethical requirements under approval from the Animal Ethics and
Experimentation Committee (ANU). Speciﬁc pathogen-free, female
BALB/c mice were obtained from ARC (Perth, Australia) or APF
(Canberra, Australia). For pathogenesis experiments, 8 week old mice
were anesthetized by inhalation of isoﬂuorane (4% in medical-grade
oxygen at 0.8 l/min) and intradermally injected with 1104 p.f.u. or
1102 p.f.u. in 10 ml PBS in the left ear pinnae (Tscharke and Smith,
1999; Lin, Smith, and Tscharke, 2012), or infected intranasally with
1104 p.f.u. or 1103 p.f.u. in a total of 20 ml of PBS (10 ml per naris).
For the dermal model, lesion sizes were estimated daily as described
previously (Tscharke and Smith, 1999; Lin et al., 2012). After intranasal
infection mice were weighed daily and monitored for signs of
infection. Severely ill mice (clinical score 46) or those that lost more
than 30% of baseline body weight that did not have an improving
clinical score were euthanized.
Titration of virus from organs
The infected ears of intradermally infected mice were collected
on day 5 p.i.. Organs were collected from intranasally infected mice
at days 3, 7 or 10 p.i.. Ears or organs were homogenized in D2.
Homogenates were frozen and thawed three times and sonicated
for 20 s three times, before titration.
Statistical analysis
Statistical comparisons were done using Prism Software (ver-
sion 5.01; GraphPad).
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